BR112014023321B1 - Composições compreendendo fagos antibacterianos e seus usos - Google Patents

Composições compreendendo fagos antibacterianos e seus usos Download PDF

Info

Publication number
BR112014023321B1
BR112014023321B1 BR112014023321-7A BR112014023321A BR112014023321B1 BR 112014023321 B1 BR112014023321 B1 BR 112014023321B1 BR 112014023321 A BR112014023321 A BR 112014023321A BR 112014023321 B1 BR112014023321 B1 BR 112014023321B1
Authority
BR
Brazil
Prior art keywords
bacteriophage
strains
phage
seq
composition
Prior art date
Application number
BR112014023321-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014023321A2 (pt
Inventor
Sofia Volker Côrte-Real
João João Duarte Alves Mendes
Clara Isabel Rodrigues Leandro
Original Assignee
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa filed Critical Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa
Publication of BR112014023321A2 publication Critical patent/BR112014023321A2/pt
Publication of BR112014023321B1 publication Critical patent/BR112014023321B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320004—Surgical cutting instruments abrasive
    • A61B2017/320008—Scrapers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
BR112014023321-7A 2012-03-19 2013-03-19 Composições compreendendo fagos antibacterianos e seus usos BR112014023321B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612531P 2012-03-19 2012-03-19
US61/612,531 2012-03-19
PCT/PT2013/000016 WO2013141730A1 (en) 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
BR112014023321A2 BR112014023321A2 (pt) 2022-02-01
BR112014023321B1 true BR112014023321B1 (pt) 2022-06-14

Family

ID=48534472

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023321-7A BR112014023321B1 (pt) 2012-03-19 2013-03-19 Composições compreendendo fagos antibacterianos e seus usos

Country Status (13)

Country Link
US (1) US9962419B2 (cg-RX-API-DMAC7.html)
EP (1) EP2833899B1 (cg-RX-API-DMAC7.html)
JP (1) JP6186427B2 (cg-RX-API-DMAC7.html)
CN (1) CN104519893B (cg-RX-API-DMAC7.html)
AU (1) AU2013235883B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014023321B1 (cg-RX-API-DMAC7.html)
CA (1) CA2867418C (cg-RX-API-DMAC7.html)
DK (1) DK2833899T3 (cg-RX-API-DMAC7.html)
ES (1) ES2814024T3 (cg-RX-API-DMAC7.html)
PT (1) PT2833899T (cg-RX-API-DMAC7.html)
RU (1) RU2654596C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201405829WA (cg-RX-API-DMAC7.html)
WO (1) WO2013141730A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
WO2016066722A2 (en) * 2014-10-28 2016-05-06 Ian Humphery-Smith Bacteriophage combinations for human or animal therapy
US10455983B2 (en) 2015-09-10 2019-10-29 Prince Castle LLC Modular food holding system
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
WO2017180862A1 (en) * 2016-04-13 2017-10-19 Northeast Ohio Medical University Gpnmb compositions for treatment of skin wounds
WO2018106135A2 (en) 2016-12-05 2018-06-14 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
JP7370867B2 (ja) 2017-02-13 2023-10-30 アルマタ・ファーマシューティカルズ・インコーポレーテッド 療法バクテリオファージ組成物
US20210065844A1 (en) * 2017-09-05 2021-03-04 Adaptive Phage Therapeutics, Inc. Methods to determine the sensitivity profile of a bacterial strain to a therapeutic composition
MX2020004251A (es) * 2017-10-19 2021-05-27 Mona E Buice Composición tópica para cicatrización mejorada de heridas abiertas.
CA3085314A1 (en) * 2017-12-11 2019-06-20 Adaptive Phage Therapeutics, Inc. Phage dispensing system
JP2021508740A (ja) * 2018-01-02 2021-03-11 アルマタ・ファーマシューティカルズ・インコーポレーテッド Staphylococcus感染症を処置するための治療的バクテリオファージ組成物
CN109082414B (zh) * 2018-06-29 2020-11-13 浙江工业大学 一种金黄色葡萄球菌噬菌体及应用
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
CN109730235A (zh) * 2019-02-01 2019-05-10 珠海横琴普罗恩能医用食品有限公司 一种用于医用食品的防腐剂
US12576118B2 (en) 2019-05-21 2026-03-17 University of Pittsburgh—of the Commonwealth System of Higher Education Bacteriophages for the treatment of tuberculosis
JP2023523319A (ja) 2020-04-27 2023-06-02 アルマタ・ファーマシューティカルズ・インコーポレーテッド シュードモナス感染症を処置するためのバクテリオファージ組成物
CN111643724B (zh) * 2020-07-01 2022-01-28 南京大学 一种载有噬菌体和酸性成纤维细胞生长因子的水凝胶伤口敷料的制备方法及其应用
WO2022013314A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh Bacteriophage cocktails and uses thereof
WO2022013318A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh New mosaic bacteriophages and uses thereof
CN112251439B (zh) * 2020-10-26 2022-06-21 齐鲁师范学院 拟南芥高温诱导启动子pHTG1及其重组载体
CN112301001B (zh) * 2020-11-03 2022-10-14 华中农业大学 金黄色葡萄球菌噬菌体lsa2311及其应用
CN113201458B (zh) * 2020-12-21 2022-05-27 青岛诺安百特生物技术有限公司 一种提高噬菌体制剂稳定性的组合物及其应用
AU2022272135A1 (en) * 2021-05-12 2024-01-04 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
WO2022261498A1 (en) * 2021-06-11 2022-12-15 Integrated Pharma Services, Llc Device and methods for acne therapeutics: antibacterial bacteriophages and engineered lysins
DE202022102100U1 (de) 2022-04-20 2022-04-27 Prabhakar Ramesh Bhandari Synergistische antibiotische pharmazeutische Zusammensetzung zur Behandlung von Staphylococcus aureus-Infektionen
EP4626449A1 (en) * 2022-11-28 2025-10-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Acinetobacter baumannii phages
WO2025104708A1 (en) 2023-11-16 2025-05-22 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Method for determining the susceptibility of bacteria to bacteriophages

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699322B2 (en) 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6138401A (en) 1999-06-25 2000-10-31 Duncan; Franklin R. Fish hook remover
CN1643139A (zh) * 2002-03-25 2005-07-20 沃里克大学 抗菌剂
US20050095222A1 (en) 2003-10-29 2005-05-05 Taro Suzuki Allergen inhibitor, allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet
EP1812025B1 (en) 2004-11-02 2012-09-05 Chr. Hansen A/S Stabilized bacteriophage formulations
MX2007005279A (es) 2004-11-02 2008-03-11 Gangagen Life Sciences Inc Composiciones de bacteriofagos.
CA2593992A1 (en) 2004-12-06 2006-06-15 Rodney M. Donlan Inhibition of biofilm formation using bacteriophage
US20080260697A1 (en) 2005-05-26 2008-10-23 Gangagen Life Sciences Inc. Bacterial Management in Animal Holding Systems
ES2761835T3 (es) * 2009-02-06 2020-05-21 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fagos antibacterianos, péptidos de fagos y métodos de uso de los mismos
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
RU2614114C2 (ru) * 2010-09-17 2017-03-22 Текнифар-Индустриа Текника Фармасьютика, С.А Бактериофаги, фаговые пептиды и способы их применения

Also Published As

Publication number Publication date
CA2867418C (en) 2020-03-10
SG11201405829WA (en) 2014-10-30
BR112014023321A2 (pt) 2022-02-01
DK2833899T3 (da) 2020-09-28
AU2013235883A1 (en) 2014-10-02
CN104519893A (zh) 2015-04-15
RU2654596C2 (ru) 2018-05-21
EP2833899B1 (en) 2020-06-24
WO2013141730A1 (en) 2013-09-26
US9962419B2 (en) 2018-05-08
HK1207002A1 (en) 2016-01-22
EP2833899A1 (en) 2015-02-11
RU2014141941A (ru) 2016-05-20
PT2833899T (pt) 2020-09-15
AU2013235883B2 (en) 2018-01-04
JP6186427B2 (ja) 2017-08-23
CA2867418A1 (en) 2013-09-26
ES2814024T3 (es) 2021-03-25
US20150150919A1 (en) 2015-06-04
JP2015512384A (ja) 2015-04-27
CN104519893B (zh) 2020-02-07

Similar Documents

Publication Publication Date Title
RU2654596C2 (ru) Композиции коктейля, содержащие антибактериальные фаги, и способы их применения
JP6944399B2 (ja) プロバイオティクス細菌
Li et al. Liposomal andrographolide dry powder inhalers for treatment of bacterial pneumonia via anti-inflammatory pathway
RU2580248C2 (ru) Бактериофаг, обладающий активностью против pseudomonas aeruginosa, белки бактериофага и способы их применения
Aswathanarayan et al. Biofilm-associated infections in chronic wounds and their management
BR112013006400B1 (pt) Composição farmacêutica e seu uso, métodos relacionados a uma infecção bacteriana
BRPI0712964A2 (pt) processo para a erradicação de elementos patogênicos compreendendo gerar iodo molecular no local
EP1585532A2 (en) Topical anti-infective formulations
WO2020073946A1 (en) Compositions comprising bacteriophages and uses thereof for the treatment or prevention of skin lesions and psoriasis
BR112020017219A2 (pt) Lisinas plyss2 modificadas e usos das mesmas
Vacek et al. Phage therapy combined with Gum Karaya injectable hydrogels for treatment of methicillin-resistant Staphylococcus aureus deep wound infection in a porcine model
Zhu et al. Antimicrobial peptide MPX with broad-spectrum bactericidal activity promotes proper abscess formation and relieves skin inflammation
US10285938B2 (en) Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring
Gencay Topical sevoflurane: An alternative treatment for pressure ulcers
JP6223444B2 (ja) 蛋白質‐脂質複合体を用いた抗生物質治療の増強
RU2715694C1 (ru) Фармацевтическая композиция для лечения глазных инфекций, вызванных метициллин-устойчивыми штаммами Staphylococcus aureus, включающая в качестве активного начала N-концевой CHAP-домен эндолизина бактериофага K Staphylococcus aureus
HK1207002B (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
CN1911442B (zh) 一种用于防治创面感染的溶葡萄球菌酶冻干粉剂
RU2825642C1 (ru) Интраназальная композиция для профилактики и/или лечения инфекций вирусной и бактериальной этиологии
CN116173192B (zh) 一种生物抑菌制剂及其应用
TW201622741A (zh) 狗圍肛腺瘤之治療方法
Vuong et al. Omentum-Derived Mesenchymal Stem Cells Promote Antibacterial Effects and Protect Endothelial Functions via PAI-1
Al-Hajjar The effect of ozonized saline solutions processed under intense electric fields in the treatment of infected necrotizing acute pancreatitis: an experimental mode
Hillebrand et al. In vitro efficacy of four potential antimicrobial substances against Klebsiella species and Streptococcus uberis isolated from bovine mastitis
CN121818905A (zh) 一种基于噬菌体内溶素80α的温敏水凝胶及其制备方法和应用

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: TECNIFAR-INDUSTRIA TECNICA FARMACEUTICA, S.A. (PT) ; TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870210072651 DE 09/08/2021, E NECESSARIO APRESENTAR A GUIA DE RECOLHIMENTO REFERENTE AO SERVICO SOLICITADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA, VISTO QUE NAO HOUVE COMPROVACAO DE PAGAMENTO APOS 10 DIAS.

B25C Requirement related to requested transfer of rights

Owner name: TECNIFAR-INDUSTRIA TECNICA FARMACEUTICA, S.A. (PT) ; TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870210072662 DE 09/08/2021, E NECESSARIO APRESENTAR DOCUMENTO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/2013, OBSERVADAS AS CONDICOES LEGAIS